EGFR and non-small cell lung carcinoma: In a single-center study involving 1506 NSCLC patients with different TNM-N stages, the rates of EGFR-TKIs sensitive mutations were 37.5%, 45.7%, 39.3%, and 32.7%, respectively, in the stages of N0, N1, N2, and N3 (p = 0.036).